

*'Real-World Data: How To Improve Data Collection and Use in Irish Healthcare'*


Aisling O'Leary, BSc(Pharm.), Ph.D.




**National Centre for  
Pharmacoeconomics**  
NCPE Ireland

# Value-based healthcare (VBH)

- Patient value = patient-relevant outcomes/costs per patient to achieve these outcomes (*Porter 2006*)
- A healthcare delivery model in which providers, including hospitals & physicians are paid based on a patient health outcomes (*NEJM Catalyst 2017*)
- Equitable, sustainable & transparent use of available resources to achieve better outcomes & experience for every person (*CEBM 2019*)



**Value based healthcare must be underpinned by ‘actionable intelligence’ to continuously transform & improve the treatment and care of patients.**



# Key enabler of value-based healthcare...information & data


- Porter Domain 6 (2006):
  - Enable a suitable **information technology** platform
  
- NEJM Catalyst (2017):
  - New healthcare delivery models stress a team-oriented approach to patient care & **sharing of patient data** so that care is co-ordinated & outcomes easily measured
  
- CEBM Recommendation 5 (2019):
  - Develop the necessary skills in value-based healthcare by training staff in **how to measure** outcomes, patient experience & resource use
  - **Challenge is the need for better data:**
    - The problems of defining, measuring & sharing data about resource use and outcomes and experiences that matter to patients are significant barriers to increasing value



# Availability of health information is key

- What do people on the ground actually need to deliver these outcomes?
- Health information that is accurate, timely & relevant
- Requires a **well-designed health information system** to allow access to quality patient information across the **entire spectrum** of the healthcare system
- For both primary and secondary use of health data

# Current sources of real world data in Ireland



## Traditional uses:

Patient care (primary use)

Pharmacovigilance studies, screening, research outputs, drug utilisation, health status, service planning, status of care etc

# Real world data vs real world evidence

Real-world **data (RWD)** are the data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources

Real-world **evidence (RWE)** is the **analysis** of real world data or data relating to patient health status &/or delivery of healthcare routinely collected from a variety of sources

# Potential users & uses of real world data

## ■ Users:

- Clinicians
- Patients
- Service providers
- Policy makers
- Regulatory agencies
- HTA agencies
- Decision makers/payers
- Industry

## ■ Uses

- Depends on the user, the user's question(s) & the data available

## Case example

# Use of RWD for health technology assessment (HTA) of new technologies

- Randomised controlled clinical trials (RCTs) remain most robust method of generating efficacy for new technologies
  
- RWD uses for HTA
  - Pre assessment setting
  - Derivation of model inputs
    - Epidemiology, natural history
    - Resource utilisation, drug utilisation, cost estimates
    - Quality of life estimates
    - Transition probabilities
    - Compliance
  - Post assessment
    - Outcome validation
    - Managed Entry Agreements
    - Managed Entry/Access Protocols

# Challenges with the use of RWD/RWE in HTA

- In estimations of comparative treatment effect
  - Multiple biases
  - Confounding
  - Important co-variables missing etc.
  
- In determination of post-approval outcomes
  - No electronic means to extract relevant information
  - No linkage to allow intelligence to be shared
  - Resource intensive

Strengths of RWD	Limitations of RWD
Ability to collect/analyse large numbers of subjects	Important clinical data may be missing
Study of choice for: <ul style="list-style-type: none"> <li>- Identifying important cohorts</li> <li>- Treatment patterns of care</li> <li>- Prediction rules</li> </ul>	Accuracy of data/endpoints <ul style="list-style-type: none"> <li>- Lack of data validation</li> <li>- Adjudication of end-points</li> </ul>
Ability to perform comparative effectiveness studies to generate hypotheses: <ul style="list-style-type: none"> <li>- Areas with no data</li> <li>- Patient cohorts/disease states in which RCTs not possible or not undertaken</li> </ul>	Comparative effectiveness studies can only be hypothesis generating for: <ul style="list-style-type: none"> <li>- Confounding by indication</li> <li>- Treatment bias</li> <li>- Immortal time bias</li> </ul>
Cost of analysis lower than RCTs	Utilisation of appropriate statistical methods to minimise confounding
Data collection mechanisms can serve multiple purposes <ul style="list-style-type: none"> <li>- Infrastructure for randomised studies</li> <li>- Quality improvement</li> </ul>	
Determining whether outcomes seen in RCTs translates into similar outcomes	
Assessing tolerability & safety	

# Supporting quality RWD/RWE


- Several guidelines & frameworks available & more on the horizon with varying focuses

- HIQA's quality data framework

- Registries


- Glicklich *et al*: Research & evidence quality
- EUNetHTA ReQuest Tool: Focus on PLEG & HTA
- Duke Margolis/FDA: Regulatory context
  - Assessment of 'Fit-for-Purpose'
    - Reliability: Data accuracy, completeness, provenance, traceability
    - Relevance: Availability of data elements & sample size

- But challenge is the absence of operational tools




eunethta

Vision paper on the sustainable availability of the proposed Registry Evaluation and Quality Standards Tool (REQuest)



# Practically how can we deliver VBH in Ireland?



**Primary use:** when health data is used to deliver health care to the individual from whom it was collected

**Secondary use:** is when health data is used outside of health care delivery for that individual.

- Translation of data to information
- Information to opinions
- Opinions to decision making

# Health information landscape in Ireland

- *Highly fragmented, 'siloised', insufficient formal co-ordination*
- *Collected by multiple organisations & individuals*
- *In different places*
- *Varying standards of quality*
- *Lack of interoperability (linkage)*
  - *Inability to share/connect*
  
- **No unique/individual patient/health identifier in use!**

**Interoperability:** the ability of computer systems or software to exchange and make use of information

# Barriers to access and use of healthcare data

Motivational barriers	<ul style="list-style-type: none"><li>• No incentive to share</li><li>• Fear of criticism/blame</li><li>• Disagreement on data use</li></ul>
Legal barriers	<ul style="list-style-type: none"><li>• Consent</li><li>• Perceived regulatory problems</li><li>• Data protection e.g. GDPR, Data Protection Impact Assessment (DPIA)</li></ul>
Technical, organisational, workload barriers	<ul style="list-style-type: none"><li>• Individual health identifier (IHI) not implemented</li><li>• Lack of metadata and standards</li><li>• Insufficient tools and technology</li></ul>
Economic, political and ethical barriers	<ul style="list-style-type: none"><li>• Lack of guidelines</li><li>• Lack of standardised procedures</li><li>• Lack of resources (legal, IT, data management)</li><li>• Absence of policies</li><li>• Who to ask?</li></ul>

# What is needed?

...*the unknown knowns?*

- A fundamental culture change and resources commitment around accessing, resourcing and using health data in Ireland
- Use of health data for the public interest should be the overarching tenet of a publicly funded health system

# How to address barriers to access and use of healthcare data (*known knowns*)

## ■ Implement the IHI

- Impossible to link data sets without the individual health identifier
- Big concerns in health care community about sharing patient identifiable information but not health data (if pseudo anonymised!)

## ■ National strategy for data sharing

- Sector wide guidance underpinned by legislation for secondary use

## ■ Legislation update

- Critical need for specific legislation around collection, use & sharing of data that is GDPR compliant

# How to address barriers to access and use of healthcare data (*known knowns*)

## ■ Involve patients

## ■ Roll out the eHealth Strategy

- Dedicated centre within eHealth that supports data sharing
- Address concerns about legal and regulatory complexity
- Address concerns around breach of confidentiality
- Allocate resources to data sharing
- Tackle low knowledge and misunderstanding around legality of data sharing
- Promote benefits of sharing
- Support technical and organisational groups including completing DPIA, DSAs, internal documentation

# Comparison with other jurisdictions

- Strong leadership, governance & management structures in place
- Legislative reform
- Individual health identifier
- Robust information architecture
- Interoperability frameworks *in situ*
- Nationwide registries
- Involvement of patients
- And more...



Canadian Institute for Health Information  
Better data. Better decisions. Healthier Canadians.

sundhed.dk

digitalhealth.gov.au

OpenSAFELY

**NHS**  
Digital



patientslikeme®

# SLÁINTECARE IMPLEMENTATION STRATEGY



## Patient is paramount

All care is planned and provided so that the patient is paramount, ensuring appropriate care pathways and seamless transition backed-up by full patient record and information.

*Go raibh mile maith agaibh.*

**Acknowledgements**

Staff of NCPE

Staff in treatment sites



**National Centre for  
Pharmacoeconomics**  
NCPE Ireland